This Phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluated the safety and preliminary efficacy of systemic administration of allogeneic mesenchymal stem cells (MSCs) in 62 patients with moderate to severe COPD. Participants received four monthly intravenous infusions of 100 million MSCs (Prochymal) or placebo and were followed for two years.
This post-hoc analysis of a Phase 1/2 randomized, placebo-controlled trial evaluated the efficacy of systemic administration of bone marrow-derived allogeneic mesenchymal stromal cells (remestemcel-L) in COPD patients stratified by baseline C-reactive protein (CRP) levels. In patients with CRP ≥ 4 mg/L, remestemcel-L treatment led to significant improvements in forced expiratory
This Phase I randomized, open-label clinical trial evaluated the safety and preliminary efficacy of autologous bone marrow mononuclear cells (BMMC), adipose-derived mesenchymal stromal cells (ADSC), and their co-infusion in 20 patients with moderate-to-severe COPD. Participants were divided into four groups: control (standard treatment), BMMC, ADSC, and co-infusion (BMMC + ADSC).
This 2012 randomized, double-blind, placebo-controlled trial evaluated the effects of daily supplementation with 250 mg of Wellmune WGP®, a yeast-derived 1,3/1,6 β-glucan, over 90 days in 100 healthy adults during peak upper respiratory tract infection (URTI) season. Participants recorded daily health logs, and URTI symptoms triggered medical assessments and blood
This 2018 review examines the antiviral properties of tea catechins, particularly epigallocatechin gallate (EGCG), against influenza and common cold viruses. Experimental studies indicate that catechins inhibit viral adsorption, replication, and neuraminidase activity, and enhance immune responses. Epidemiological studies suggest that regular green tea consumption and catechin-based gargling may reduce the
This 2012 review presents data from two preliminary, double-blind, randomized, placebo-controlled trials assessing the efficacy of a combination of 1000 mg vitamin C and 10 mg zinc in treating the common cold. While individual studies showed a nonsignificant reduction in rhinorrhoea duration (9–27%), pooled analysis of 94 participants demonstrated a
This 1992 randomized, double-blind, placebo-controlled trial assessed the efficacy of zinc gluconate lozenges in treating the common cold. Seventy-three young adults received either a glycine-buffered zinc gluconate lozenge (delivering 93% bioavailable zinc) or placebo. The zinc group experienced a significant reduction in symptom duration—4.9 days versus 6.1 days in the
This 2019 review in American Family Physician outlines evidence-based strategies for managing the common cold. It emphasizes that the condition is self-limiting, with symptoms typically resolving within 7–10 days. Symptomatic treatments include analgesics like acetaminophen or NSAIDs for pain and fever, decongestants for nasal congestion, and antihistamines for rhinorrhea. The
This 2011 letter to the editor critiques a prior case report suggesting a link between phentermine monotherapy and pulmonary arterial hypertension (PAH). The authors argue that the case likely represents idiopathic PAH rather than being induced by phentermine. They reference epidemiological studies indicating no significant association between phentermine use and
This 1997 editorial by M. Deitel discusses findings from a multicenter case-control study involving 95 patients with primary pulmonary hypertension (PPH) and 355 matched controls. The study identified a significant association between the use of anorexic agents, particularly fenfluramine derivatives, and the development of PPH. The risk increased with longer
